CWF19L1 Inhibitors
CWF19L1 inhibitors encompass a variety of chemical compounds that act on different stages of the cell cycle to exert their effects. Given CWF19L1's role in cell cycle control, inhibitors such as cyclin-dependent kinase inhibitors are particularly relevant. These inhibitors work by enforcing a G1 phase cell cycle arrest, which would be expected to downregulate the activity of CWF19L1, as it is implicated in the progression of the cell cycle. With the cell cycle halted in G1, CWF19L1's functional relevance in subsequent cell cycle phases would be compromised. Additionally, the use of DNA damage-inducing agents, such as PARP inhibitors, could indirectly affect CWF19L1 by triggering cell cycle checkpoints and DNA damage responses, thereby potentially reducing its activity. These checkpoints, once activated due to inhibited DNA repair, can induce a cellular environment that is not conducive to CWF19L1 activity, as its normal role may be in cell cycle phases that are not reachable when DNA damage is not repaired effectively.
Secondary mechanisms of inhibition also play a role in the functional suppression of CWF19L1. Compounds such as DNA polymerase and ribonucleotide reductase inhibitors can cause S phase arrestor imbalances in nucleotide pools, leading to cell cycle blocks. Since CWF19L1 is associated with cell cycle progression, its activity would likely be decreased in response to these disruptions. The induced S phase arrest prevents the cell from progressing past a point where CWF19L1 could act, thereby indirectly inhibiting its function. Furthermore, another layer of regulation is provided by chemicals that result in the accumulation of DNA damage. By stalling the cell cycle due to unresolved DNA lesions, these chemicals indirectly inhibit CWF19L1 by enforcing a cellular state that precludes the normal functioning of cell cycle-related proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that can suppress various kinases within the cell cycle signaling pathways, which may indirectly inhibit CWF19L1 by disrupting its associated kinase-dependent regulation mechanisms during cell cycle control. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Targets cyclin-dependent kinases (CDKs) which are essential for the regulation of the cell cycle, potentially diminishing the functional capacity of CWF19L1 in cell cycle control by interfering with CDK activity. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Inhibits cyclin-dependent kinases and could interfere with the cell cycle control in which CWF19L1 is involved by hindering the phosphorylation status of proteins regulated by these kinases. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Selectively inhibits CDKs, and by doing so, it may impair the cell cycle progression and thus indirectly affect the functional activity of CWF19L1 in regulating cell cycle events. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Could indirectly inhibit CWF19L1 by affecting the DNA synthesis phase of the cell cycle, during which CWF19L1 may exert its regulatory functions. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Topoisomerase I inhibitor that could indirectly inhibit CWF19L1 by disrupting DNA replication and transcription processes, potentially impairing the cell cycle progression where CWF19L1 may play a role. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
By destabilizing microtubules, it can disrupt mitotic spindle formation and arrest cells in the M-phase, possibly leading to the inhibition of CWF19L1's role in cell cycle control at this phase. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor which may indirectly inhibit CWF19L1 by preventing the cell cycle progression from the G1 to the S phase, a process that CWF19L1 may be involved in regulating. | ||||||
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $82.00 $300.00 $1082.00 | 30 | |
DNA polymerase alpha and delta inhibitor that could indirectly inhibit CWF19L1 by blocking DNA synthesis, thus potentially affecting the protein's role in cell cycle checkpoints or DNA repair mechanisms. | ||||||
UCN-01 | 112953-11-4 | sc-202376 | 500 µg | $246.00 | 10 | |
Inhibits several kinases involved in cell cycle control and could indirectly inhibit CWF19L1 by altering the phosphorylation of proteins that participate in cell cycle checkpoints where CWF19L1 is implicated. | ||||||